Infants with type 1 retinopathy of prematurity treated with primary bevacizumab often display normal visual acuity after 4 years of age, according to a speaker at the virtual American Academy of Ophthalmology annual meeting.
“The results of this study constitute preliminary evidence that visual outcomes in IVB-treated ROP patients after 4 years of age are likely excellent, and vascular abnormalities on fluorescein are not incompatible with good vision,” Sarah Hilkert Rodriguez, MD, said.
A retrospective chart review examining infants treated with bevacizumab for type 1 ROP found
Uncategorized